HeartRhythm

MAY 7, 2024

Implantable cardioverter defibrillator (ICD) prevents sudden cardiac death (SCD) in patients with ischemic cardiomyopathy (ICM). Catheter ablation has been shown to effectively reduce ventricular tachycardia (VT) recurrence, yet its efficacy in patients without an ICD implantation remains uncertain.

Sudden Cardiac Death 45

Sudden Cardiac Death Tachycardia Cardiomyopathy Ablation 45

HeartRhythm

FEBRUARY 1, 2025

The best approach for ablating ventricular tachycardia (VT) targeting right ventricular free wall (RVFW) aneurysms in arrhythmogenic right ventricular cardiomyopathy (ARVC) remains undefined.

Aneurysm 45

Aneurysm Tachycardia Cardiomyopathy Ablation 45

Journal of Cardiovascular Electrophysiology

NOVEMBER 7, 2024

Catheter ablation of atrial fibrillation in infiltrative cardiomyopathies ABSTRACT Atrial and ventricular arrhythmias are common in patients with Infiltrative heart diseases. Scant reports regarding ablation are described for HH and glycogen storage disorders. Future large-scale trials are needed to confirm these findings.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Cardiomyopathy Arrhythmia 40

American College of Cardiology

MAY 1, 2024

In this week’s View, Dr. Eagle looks at the durability of pulmonary vein isolation using pulsed-field ablation, then examines genetic penetrance of dilated cardiomyopathy in genotype-positive relatives.

Cardiomyopathy 49

Cardiomyopathy Pulmonary Ablation TAVR 49

DAIC

JUNE 4, 2024

American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Peripheral Arterial Disease Heart Failure Atrial Fibrillation 105

HeartRhythm

APRIL 2, 2024

Cheng and Zhang to our paper1, we note that despite ARVC being a relatively uncommon cardiomyopathy, we uniquely report on a large clinical experience with very long-term follow-up after VT ablation and confirm a high incidence of atrial flutter (AFL) and the effectiveness and low risk of catheter ablation of AFL.

Cardiomyopathy 45

Cardiomyopathy Ablation Atrial Flutter Arrhythmia 45

Journal of Cardiothoracic Surgery

SEPTEMBER 22, 2024

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a family inherited cardiomyopathy associated with ventricular arrhythmias. With the development of molecular biology, histology, imaging, and other dia.

Cardiomyopathy 52

Cardiomyopathy Tachycardia Arrhythmia Ablation 52

American College of Cardiology

OCTOBER 23, 2024

What is the impact of atrial fibrillation (AF) catheter ablation in patients with hypertrophic cardiomyopathy (HCM) on reduction in AF burden and symptoms?

Ablation 51

Ablation Atrial Fibrillation Cardiomyopathy Article 51

Frontiers in Cardiovascular Medicine

OCTOBER 7, 2024

BackgroundSigmoid Ventricular Septum (SVS) is a type of hypertrophic cardiomyopathy characterized by a reduced angle between the basal interventricular septum and the ascending aorta, and SVS can lead to dynamic Left Ventricular Outflow Tract obstruction (LVOTO) during hypercontractile states.

Ablation 59

Ablation Angina Chest Pain Echocardiogram 59

HeartRhythm

APRIL 30, 2024

Catheter ablation is an effective tool to reduce ventricular tachycardia (VT) burden. There is a lack of robust data studying the intraprocedural characteristics and outcomes of VT ablation in patients with non-ischemic (NICM) versus ischemic cardiomyopathy (ICM).

Tachycardia 40

Tachycardia Cardiomyopathy Ablation Outcomes 40

American College of Cardiology

NOVEMBER 16, 2024

Among patients with ischemic cardiomyopathy and ventricular tachycardia (VT), catheter ablation as a first-line strategy over antiarrhythmic drugs (AAD) was associated with a lower risk of the primary outcome, according to results of the VANISH2 trial.

Ablation 51

Ablation Tachycardia Cardiomyopathy Outcomes 51

Journal of Cardiothoracic Surgery

JULY 15, 2024

The feasibility of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) for the treatment of hypertrophic obstructive cardiomyopathy (HOCM) has been previously reported. However, limited invest.

Ablation 52

Ablation Risk Factors Cardiomyopathy Research 52

HeartRhythm

APRIL 30, 2024

Catheter ablation is recommended in patients with suspected atrial fibrillation-mediated cardiomyopathy (AMC) for the recovery of cardiac function.

Atrial Fibrillation 40

Atrial Fibrillation Cardiac Function Cardiomyopathy Ablation 40

Journal of Cardiovascular Electrophysiology

AUGUST 26, 2024

Abstract Introduction Due to its unique features, pulsed field ablation (PFA) could potentially overcome some limitations of current radiofrequency (RF) ventricular tachycardia (VT) ablation. Methods Two patients with ischemic cardiomyopathy and previously failed RF VT ablations were treated with PFA.

Ablation 40

Ablation Tachycardia Cardiomyopathy Technology 40

Journal of Cardiothoracic Surgery

APRIL 12, 2024

To date, the extended Morrow procedure is considered the gold standard treatment for patients with obstructive hypertrophic cardiomyopathy who experience severe symptoms and are unresponsive to medication trea.

Cardiomyopathy 52

Cardiomyopathy Ablation Outcomes Research 52

The American Journal of Cardiology

JANUARY 31, 2024

Alcohol septal ablation (ASA) is a well-established procedure for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy, s…

Cardiomyopathy 40

Cardiomyopathy Ablation 40

HeartRhythm

APRIL 30, 2024

Arrhythmias are common in patients with hypertrophic cardiomyopathy (HCM) and are associated with increased morbidity and mortality. Catheter ablation (CA) procedures have become the mainstay of treatment in patients with VAs however the safety of these procedures is not well studied in HCM.

Arrhythmia 40

Arrhythmia Cardiomyopathy Ablation Outcomes 40

American College of Cardiology

JUNE 11, 2024

Endocardial (ENDO)-only ventricular tachycardia (VT) ablation has been found to indicate long-term VT-free survival in more than half of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) and more than 75% if VT noninducibility is achieved following ablation.

Ablation 49

Ablation Tachycardia Cardiomyopathy Article 49

HeartRhythm

AUGUST 23, 2023

Atrial fibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HCM) and can be challenging to manage. Atrioventricular nodal (AVN) ablation may be an effective management strategy for AF in these patients.

Atrial Fibrillation 40

Atrial Fibrillation Cardiomyopathy Ablation 40

HeartRhythm

APRIL 30, 2024

Catheter ablation (CA) is effective in the treatment of ventricular tachycardia (VT). Although some data suggest patients with non-ischemic cardiomyopathy (NCIM) have worse outcomes compared to those with an ischemic etiology (ICM), direct comparisons are scarcely reported.

Tachycardia 40

Tachycardia Cardiomyopathy Ablation Outcomes 40

HeartRhythm

DECEMBER 16, 2024

A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrial fibrillation (AF) is still reported.1

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Cardiomyopathy Ablation 40

Frontiers in Cardiovascular Medicine

AUGUST 8, 2024

BackgroundAbnormal substrate on invasive electroanatomic mapping (EAM) correlates with areas of myocardial thinning and fibrofatty replacement in Arrhythmogenic Cardiomyopathy (ACM).

Cardiomyopathy 52

Cardiomyopathy Tricuspid Echocardiogram Electrophysiology 52

HeartRhythm

DECEMBER 26, 2024

Surgical disarticulation of the right ventricular (RV) free wall has been described by Guiraudon and colleagues as an effective therapy for refractory ventricular tachycardia (VT) in arrhythmogenic right ventricular cardiomyopathy (ARVC).1

Cardiomyopathy 45

Cardiomyopathy Tachycardia Ablation 45

European Journal of Heart Failure

FEBRUARY 25, 2025

Overview of the study population and effects observed after catheter ablation for atrial fibrillation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. to 39.18.3% ( p <0.001) following ablation. PVI, pulmonary vein isolation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Epicardial catheter ablation of ventricular tachycardia (VT) is a well-established ablation technique for a variety of myocardial substrates including ischemic cardiomyopathy. Epicardial VT ablation has several potential life-threatening complications including a 1.5% incidence of coronary artery (CA) injury.

Ablation 40

Ablation Coronary Artery Disease Cardiomyopathy Tachycardia 40

Journal of Cardiothoracic Surgery

JANUARY 6, 2025

Tachycardia-induced cardiomyopathy refers to changes in cardiac structure and function that result from rapid arrhythmia and can manifest as a continuous or recurrent event. Cardiomyopathy induced by atrial ta.

Cardiomyopathy 40

Cardiomyopathy Tachycardia Arrhythmia Ablation 40

HeartRhythm

DECEMBER 5, 2023

As a result, different alternative septal reduction approaches, including transapical septal myomectomy 4, and even catheter-based radiofrequency ablation 5 have been described.

Ablation 45

Ablation Arrhythmia Cardiomyopathy 45

Heart BMJ

MAY 10, 2024

Objective The objective is to evaluate the 5-year follow-up results of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) for hypertrophic obstructive cardiomyopathy (HOCM), including clinical status, electrocardiographic and echocardiographic characteristics. Methods 27 patients (age: 44.3±15.5

Ablation 52

Ablation Exercise Heart Failure Cardiomyopathy 52

The British Journal of Cardiology

DECEMBER 3, 2024

Atrioventricular nodal (AVN) ablation with permanent pacemaker implantation – ‘pace and ablate’ – may be considered for patients with symptomatic atrial fibrillation (AF) for whom rhythm control has been unsuccessful. This creates concerns about inducing pacemaker dependence and potential pacemaker-induced cardiomyopathy (PICM).

Ablation 40

Ablation Pacemaker Atrial Fibrillation Physiology 40

HeartRhythm

APRIL 23, 2024

70 y/o woman with a history of ischemic cardiomyopathy with ejection fraction of 20% due to a large healed anteroapical infarction.

Tachycardia 40

Tachycardia Ablation Cardiomyopathy Hospital 40

HeartRhythm

NOVEMBER 10, 2023

In arrhythmogenic right ventricular cardiomyopathy (ARVC), risk of atrial arrhythmias (AA) persists after ventricular tachycardia (VT) ablation.

Tachycardia 40

Tachycardia Arrhythmia Cardiomyopathy Ablation 40

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) is highly prevalent in patients with hypertrophic cardiomyopathy (HCM) as well as other cardiomyopathy (CM) phenotypes.

Atrial Fibrillation 40

Atrial Fibrillation Cardiomyopathy Ablation 40

HeartRhythm

JUNE 3, 2024

Recent advancements in catheter ablation for structural ventricular tachycardia (VT), such as high-density mapping and cardiac imaging-based detection of target areas, have significantly improved the efficacy of ablation procedures.

Sudden Cardiac Death 40

Sudden Cardiac Death Tachycardia Ablation Defibrillator 40

HeartRhythm

SEPTEMBER 19, 2023

In patients with hypertrophic cardiomyopathy (HCM), atrial fibrillation (AF) poses significant clinical challenges because of its adverse impact on hemodynamics. AF, especially when accompanied by rapid ventricular responses, compromises atrial contraction and in turn increases diastolic filling of the left ventricle.

Atrial Fibrillation 40

Atrial Fibrillation Cardiomyopathy Ablation Heart Failure 40

HeartRhythm

APRIL 30, 2024

Current literature is limited in direct comparison of VT in ischemic (ICM) compared to non-ischemic cardiomyopathy (NICM). Ventricular Tachycardia (VT) is an important cause of morbidity and mortality in structural heart Disease.

Tachycardia 40

Tachycardia Cardiomyopathy Heart Disease Ablation 40

HeartRhythm

JUNE 24, 2024

Recently, the involvement of the Purkinje network has been proven in some patients with hypertrophic cardiomyopathy (HCM).1,2 1,2 Ablation targeting the distal Purkinje fibers is effective in reducing the VF burden.

Cardiomyopathy 40

Cardiomyopathy Ablation Heart Disease 40

Frontiers in Cardiovascular Medicine

JANUARY 8, 2025

Recent research has identified cases of sustained FAT originating from the interatrial septum (IAS); a subset of cases presents a unique challenge, with foci originating from the peri-patent foramen ovale (peri-PFO), requiring specialized management during catheter ablation.

Tachycardia 40

Tachycardia Ablation Cardiomyopathy Electrocardiogram 40